BPG is committed to discovery and dissemination of knowledge
Case Report
Copyright: ©Author(s) 2026.
World J Crit Care Med. Sep 9, 2026; 15(3): 120702
Published online Sep 9, 2026. doi: 10.5492/wjccm.120702
Table 1 Clinical timeline and treatment milestones
Timepoint
Clinical status and diagnostic findings
Interventions and management
Day 1 (admission)GCS 3 (E1V1M1); signs of cholinergic toxidrome (miosis, secretions, shock)Intubation, mechanical ventilation, and IV atropine infusion
Day 1 (ICU)Refractory shock; non-responsive to atropine. CECT shows grade 2 corrosive edemaDual vasopressors (noradrenaline + vasopressin) initiated
Day 2Comatose with fixed pupils. Refractory vasoplegic shock. Toxicology samples sentFirst dose MB (100 mg IV) administered as rescue therapy
Day 2 (post-MB)Significant hemodynamic stabilization; vasopressors taperedMRI brain performed (revealing CLOCC pattern/toxic encephalopathy)
Day 3Sensorium remains low. Toxicology confirms nickel toxicity (blood, urine, and CSF)Second dose MB (100 mg IV); high-dose PPI continued
Day 4Hemodynamics stable. Significant drop in serum nickel; spike in urinary clearanceThird dose MB (100 mg IV)
Day 5Rapid neurological recovery; GCS improves to 11 (E4VTM6)Vasopressors discontinued; patient successfully extubated
Day 7Patient alert and oriented (GCS 15)Transitioned to oral intake; prepared for discharge
Table 2 Longitudinal nickel concentrations in relation to methylene blue administration
Timepoint
Blood nickel (μg/L)
Urine nickel (μg/L)
CSF nickel (μg/L)
Baseline (after 1st dose MB)15.221.0-
Before 3rd dose MB7.48.855.5
After 3rd dose MB4.851.9-
48 hours post-3rd dose3.71.8-
72 hours post-3rd dose2.15.6-
96 hours post-3rd dose0.00.0-
Reference range0.14-0.65< 5.2-


Write to the Help Desk